Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19 - Nasdaq

--Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform ... Read More

Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer - Yahoo Finance

Trial Supported in Part by NIH SBIR GrantMALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing ... Read More

Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer - Markets Insider

Initiation builds on positive overall survival and tumor control data from Phase 1/2 trial Triggers $20M milestone payment from Blackstone Life Sciences 160-patient randomized, multicenter ... Read More

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia November 13, 2024 04:05 PM Eastern Standard Time ... Read More

Seneca Therapeutics Announces the Dosing of the First Patient in the SVV-001 Phase I/II Trial - WAVY.com

Seneca Therapeutics Announces the Dosing of the First Patient in the SVV-001 Phase I/II Trial. ... These statements are made as of the date of this press release. Read More

Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial - Business Wire

Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID ... randomized, double-blind, ... of FM outcome measures was previously demonstrated in a Phase 2a clinical trial. Read More

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion ...

First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID) ... Read More

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 ...

The SPY002 and SPY072 Phase 1 trials are first-in-human, randomized, double-blind, ... Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two ... SKYWAY-RD Phase 2 clinical trial ... Read More

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment ... - Morningstar

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure Provided by ... Read More

Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors - WHNT News 19

DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics ... Read More

Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19 - Yahoo Finance

MALVERN, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel ... Read More